{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,6,5]],"date-time":"2024-06-05T00:25:28Z","timestamp":1717547128775},"reference-count":40,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2024,4,18]],"date-time":"2024-04-18T00:00:00Z","timestamp":1713398400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,4,18]],"date-time":"2024-04-18T00:00:00Z","timestamp":1713398400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Arch Dermatol Res"],"DOI":"10.1007\/s00403-024-02862-z","type":"journal-article","created":{"date-parts":[[2024,4,18]],"date-time":"2024-04-18T17:01:36Z","timestamp":1713459696000},"update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Understanding patient perspectives on vaccine decision making in adults with autoimmune bullous diseases: a qualitative study"],"prefix":"10.1007","volume":"316","author":[{"given":"Alice J.","family":"Tan","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marjorie","family":"Archila","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"John S.","family":"Barbieri","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Arash","family":"Mostaghimi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aaron M.","family":"Scherer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lourdes M.","family":"Perez-Chada","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maryam M.","family":"Asgari","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joel M.","family":"Gelfand","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Megan H.","family":"Noe","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2024,4,18]]},"reference":[{"key":"2862_CR1","unstructured":"Genentech I. Rituxan (rituximab) [package insert], Food US, Administration D (2023) https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2021\/103705s5464lbl.pdf. Revised June 2021. Accessed December 21"},{"key":"2862_CR2","unstructured":"(2019) Ten threats to global health in 2019, World Health Organization (WHO). https:\/\/www.who.int\/news-room\/spotlight\/ten-threats-to-global-health-in-2019. Accessed December 21, 2023"},{"key":"2862_CR3","unstructured":"(2022) Immunization, The United Nations Children\u2019s Fund (UNICEF). https:\/\/data.unicef.org\/topic\/child-health\/immunization\/. Accessed December 21, 2023"},{"key":"2862_CR4","unstructured":"Alexander C, (2023) How Much Does a Shingles Vaccine Cost? GoodRx Health. https:\/\/www.goodrx.com\/conditions\/shingles\/shingles-vaccine-cost-shingrix. Accessed December 21, 2023"},{"issue":"3","key":"2862_CR5","doi-asserted-by":"publisher","first-page":"449","DOI":"10.1002\/art.42386","volume":"75","author":"AR Bass","year":"2023","unstructured":"Bass AR, Chakravarty E, Akl EA, Bingham CO, Calabrese L, Cappelli LC, Johnson SR, Imundo LF, Winthrop KL, Arasaratnam RJ, Baden LR, Berard R, Bridges SL Jr., Cheah JTL, Curtis JR, Ferguson PJ, Hakkarinen I, Onel KB, Schultz G, Sivaraman V, Smith BJ, Sparks JA, Vogel TP, Williams EA, Calabrese C, Cunha JS, Fontanarosa J, Gillispie-Taylor MC, Gkrouzman E, Iyer P, Lakin KS, Legge A, Lo MS, Lockwood MM, Sadun RE, Singh N, Sullivan N, Tam H, Turgunbaev M, Turner AS, Reston J (2023) 2022 American College of Rheumatology Guideline for Vaccinations in patients with Rheumatic and Musculoskeletal diseases. Arthritis Care Res (Hoboken) 75(3):449\u2013464. https:\/\/doi.org\/10.1002\/art.42386","journal-title":"Arthritis Care Res (Hoboken)"},{"issue":"2","key":"2862_CR6","doi-asserted-by":"publisher","first-page":"254","DOI":"10.1111\/bjd.21042","volume":"187","author":"K Bechman","year":"2022","unstructured":"Bechman K, Cook ES, Dand N, Yiu ZZN, Tsakok T, Meynell F, Coker B, Vincent A, Bachelez H, Barbosa I, Brown MA, Capon F, Contreras CR, De La Cruz C, Meglio PD, Gisondi P, Jullien D, Kelly J, Lambert J, Lancelot C, Langan SM, Mason KJ, McAteer H, Moorhead L, Naldi L, Norton S, Puig L, Spuls PI, Torres T, Urmston D, Vesty A, Warren RB, Waweru H, Weinman J, Griffiths CEM, Barker JN, Smith CH, Galloway JB, Mahil SK, PsoProtect study g (2022) Vaccine hesitancy and access to psoriasis care during the COVID-19 pandemic: findings from a global patient-reported cross-sectional survey. Br J Dermatol 187(2):254\u2013256. https:\/\/doi.org\/10.1111\/bjd.21042","journal-title":"Br J Dermatol"},{"key":"2862_CR7","doi-asserted-by":"publisher","unstructured":"Bingham CO 3rd, Looney RJ, Deodhar A, Halsey N, Greenwald M, Codding C, Trzaskoma B, Martin F, Agarwal S, Kelman A (2010) Immunization responses in rheumatoid arthritis patients treated with rituximab: results from a controlled clinical trial. Arthritis Rheum 62(1):64\u201374. https:\/\/doi.org\/10.1002\/art.25034","DOI":"10.1002\/art.25034"},{"issue":"2","key":"2862_CR8","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1111\/bjd.21240","volume":"187","author":"M Birabaharan","year":"2022","unstructured":"Birabaharan M, Kaelber DC, Orme CM, Paravar T, Karris MY (2022) Evaluating risk of bullous pemphigoid after mRNA COVID-19 vaccination. Br J Dermatol 187(2):271\u2013273. https:\/\/doi.org\/10.1111\/bjd.21240","journal-title":"Br J Dermatol"},{"issue":"9","key":"2862_CR9","doi-asserted-by":"publisher","first-page":"1585","DOI":"10.1093\/rheumatology\/kez045","volume":"58","author":"S Buhler","year":"2019","unstructured":"Buhler S, Jaeger VK, Adler S, Bannert B, Brummerhoff C, Ciurea A, Distler O, Franz J, Gabay C, Hagenbuch N, Herzog C, Hasler P, Kling K, Kyburz D, Muller R, Nissen MJ, Siegrist CA, Villiger PM, Walker UA, Hatz C (2019) Safety and immunogenicity of tetanus\/diphtheria vaccination in patients with rheumatic diseases-a prospective multi-centre cohort study. Rheumatology (Oxford) 58(9):1585\u20131596. https:\/\/doi.org\/10.1093\/rheumatology\/kez045","journal-title":"Rheumatology (Oxford)"},{"key":"2862_CR10","doi-asserted-by":"publisher","first-page":"101113","DOI":"10.1016\/j.eclinm.2021.101113","volume":"40","author":"F Cascini","year":"2021","unstructured":"Cascini F, Pantovic A, Al-Ajlouni Y, Failla G, Ricciardi W (2021) Attitudes, acceptance and hesitancy among the general population worldwide to receive the COVID-19 vaccines and their contributing factors: a systematic review. EClinicalMedicine 40:101113. https:\/\/doi.org\/10.1016\/j.eclinm.2021.101113","journal-title":"EClinicalMedicine"},{"key":"2862_CR11","unstructured":"Celentano D, Szklo M (2018) Gordis Epidemiology. Elsevier"},{"key":"2862_CR12","unstructured":"(2022) The Inflation Reduction Act Lowers Health Care Costs for Millions of Americans, Centers for Medicare and Medicaid Services. https:\/\/www.cms.gov\/priorities\/legislation\/inflation-reduction-act-and-medicare\/lowers-health-care-costs-millions-americans\/. Accessed December, 21 2023"},{"issue":"5","key":"2862_CR13","doi-asserted-by":"publisher","first-page":"R171","DOI":"10.1186\/ar4358","volume":"15","author":"M Crnkic Kapetanovic","year":"2013","unstructured":"Crnkic Kapetanovic M, Saxne T, Jonsson G, Truedsson L, Geborek P (2013) Rituximab and abatacept but not tocilizumab impair antibody response to pneumococcal conjugate vaccine in patients with rheumatoid arthritis. Arthritis Res Ther 15(5):R171. https:\/\/doi.org\/10.1186\/ar4358","journal-title":"Arthritis Res Ther"},{"key":"2862_CR14","unstructured":"Cubanski J, Damico A, August 17 (2022) Key Facts About Medicare Part D Enrollment and Costs in 2022, KFF (Kaiser Family Foundation). https:\/\/www.kff.org\/medicare\/issue-brief\/key-facts-about-medicare-part-d-enrollment-and-costs-in-2022\/. Accessed December, 21 2023"},{"issue":"10","key":"2862_CR15","doi-asserted-by":"publisher","first-page":"e645","DOI":"10.1111\/jdv.17472","volume":"35","author":"G Damiani","year":"2021","unstructured":"Damiani G, Pacifico A, Pelloni F, Iorizzo M (2021) The first dose of COVID-19 vaccine may trigger pemphigus and bullous pemphigoid flares: is the second dose therefore contraindicated? J Eur Acad Dermatol Venereol 35(10):e645\u2013e647. https:\/\/doi.org\/10.1111\/jdv.17472","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"4","key":"2862_CR16","doi-asserted-by":"publisher","first-page":"728","DOI":"10.1111\/bjd.20890","volume":"186","author":"T Gambichler","year":"2022","unstructured":"Gambichler T, Hamdani N, Budde H, Sieme M, Skrygan M, Scholl L, Dickel H, Behle B, Ganjuur N, Scheel C, Abu Rached N, Ocker L, Stranzenbach R, Doerler M, Pfeiffer L, Becker JC (2022) Bullous pemphigoid after SARS-CoV-2 vaccination: spike-protein-directed immunofluorescence confocal microscopy and T-cell-receptor studies. Br J Dermatol 186(4):728\u2013731. https:\/\/doi.org\/10.1111\/bjd.20890","journal-title":"Br J Dermatol"},{"issue":"7","key":"2862_CR17","doi-asserted-by":"publisher","first-page":"1016","DOI":"10.1002\/acr.22246","volume":"66","author":"C Hua","year":"2014","unstructured":"Hua C, Barnetche T, Combe B, Morel J (2014) Effect of methotrexate, anti-tumor necrosis factor alpha, and rituximab on the immune response to influenza and pneumococcal vaccines in patients with rheumatoid arthritis: a systematic review and meta-analysis. Arthritis Care Res (Hoboken) 66(7):1016\u20131026. https:\/\/doi.org\/10.1002\/acr.22246","journal-title":"Arthritis Care Res (Hoboken)"},{"issue":"4","key":"2862_CR18","doi-asserted-by":"publisher","first-page":"531","DOI":"10.1080\/00039896.1966.10664421","volume":"12","author":"SV Kasl","year":"1966","unstructured":"Kasl SV, Cobb S (1966) Health behavior, illness behavior, and sick-role behavior. II. Sick-role behavior. Arch Environ Health 12(4):531\u2013541. https:\/\/doi.org\/10.1080\/00039896.1966.10664421","journal-title":"Arch Environ Health"},{"issue":"7","key":"2862_CR19","doi-asserted-by":"publisher","first-page":"e412","DOI":"10.1111\/jdv.17207","volume":"35","author":"M Kasperkiewicz","year":"2021","unstructured":"Kasperkiewicz M, Schmidt E, Amagai M, Fairley JA, Joly P, Murrell DF, Payne AS, Yale ML, Zillikens D, Woodley DT (2021) Updated international expert recommendations for the management of autoimmune bullous diseases during the COVID-19 pandemic. J Eur Acad Dermatol Venereol 35(7):e412\u2013e414. https:\/\/doi.org\/10.1111\/jdv.17207","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"4","key":"2862_CR20","doi-asserted-by":"publisher","first-page":"737","DOI":"10.1111\/bjd.20906","volume":"186","author":"M Kasperkiewicz","year":"2022","unstructured":"Kasperkiewicz M, Strong R, Mead K, Yale M, Zillikens D, Woodley DT, Recke A (2022) COVID-19 vaccine acceptance and hesitancy in patients with immunobullous diseases: a cross-sectional study of the International Pemphigus and Pemphigoid Foundation. Br J Dermatol 186(4):737\u2013739. https:\/\/doi.org\/10.1111\/bjd.20906","journal-title":"Br J Dermatol"},{"issue":"1","key":"2862_CR21","doi-asserted-by":"publisher","first-page":"e9","DOI":"10.1111\/jdv.18493","volume":"37","author":"M Kasperkiewicz","year":"2023","unstructured":"Kasperkiewicz M, Strong R, Yale M, Dunn P, Woodley DT (2023) Safety of the COVID-19 vaccine booster in patients with immunobullous diseases: a cross-sectional study of the International Pemphigus and Pemphigoid Foundation. J Eur Acad Dermatol Venereol 37(1):e9\u2013e10. https:\/\/doi.org\/10.1111\/jdv.18493","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"5","key":"2862_CR22","doi-asserted-by":"publisher","first-page":"1160","DOI":"10.1016\/j.jaad.2021.04.061","volume":"86","author":"M Kasperkiewicz","year":"2022","unstructured":"Kasperkiewicz M, Woodley DT (2022) Association between vaccination and autoimmune bullous diseases: a systematic review. J Am Acad Dermatol 86(5):1160\u20131164. https:\/\/doi.org\/10.1016\/j.jaad.2021.04.061","journal-title":"J Am Acad Dermatol"},{"key":"2862_CR23","doi-asserted-by":"publisher","first-page":"E04","DOI":"10.5888\/pcd17.200355","volume":"18","author":"S Keddem","year":"2021","unstructured":"Keddem S, Barg FK, Frasso R (2021) Practical Guidance for studies using freelisting interviews. Prev Chronic Dis 18:E04. https:\/\/doi.org\/10.5888\/pcd17.200355","journal-title":"Prev Chronic Dis"},{"issue":"4","key":"2862_CR24","doi-asserted-by":"publisher","first-page":"499","DOI":"10.1093\/bjd\/ljac118","volume":"188","author":"K Kridin","year":"2023","unstructured":"Kridin K, Mruwat N, Amber KT, Ludwig RJ (2023) Risk of infections in patients with pemphigus treated with Rituximab vs. azathioprine or mycophenolate mofetil: a large-scale global cohort study. Br J Dermatol 188(4):499\u2013505. https:\/\/doi.org\/10.1093\/bjd\/ljac118","journal-title":"Br J Dermatol"},{"issue":"5","key":"2862_CR25","doi-asserted-by":"publisher","first-page":"607","DOI":"10.2340\/00015555-2611","volume":"97","author":"K Kridin","year":"2017","unstructured":"Kridin K, Sagi SZ, Bergman R (2017) Mortality and cause of death in patients with Pemphigus. Acta Derm Venereol 97(5):607\u2013611 10.2340\/00015555\u2009\u2013\u20092611","journal-title":"Acta Derm Venereol"},{"issue":"5","key":"2862_CR26","doi-asserted-by":"publisher","first-page":"1149","DOI":"10.1111\/j.1365-2133.2009.09350.x","volume":"161","author":"SM Langan","year":"2009","unstructured":"Langan SM, Hubbard R, Fleming K, West J (2009) A population-based study of acute medical conditions associated with bullous pemphigoid. Br J Dermatol 161(5):1149\u20131152. https:\/\/doi.org\/10.1111\/j.1365-2133.2009.09350.x","journal-title":"Br J Dermatol"},{"issue":"8","key":"2862_CR27","doi-asserted-by":"publisher","first-page":"613","DOI":"10.1111\/1346-8138.12175","volume":"40","author":"JS Lehman","year":"2013","unstructured":"Lehman JS, Khunger M, Lohse CM (2013) Infection in autoimmune bullous diseases: a retrospective comparative study. J Dermatol 40(8):613\u2013619. https:\/\/doi.org\/10.1111\/1346-8138.12175","journal-title":"J Dermatol"},{"issue":"4","key":"2862_CR28","doi-asserted-by":"publisher","first-page":"591","DOI":"10.1016\/j.det.2011.06.021","volume":"29","author":"JS Lehman","year":"2011","unstructured":"Lehman JS, Murrell DF, Camilleri MJ, Kalaaji AN (2011) Infection and infection prevention in patients treated with immunosuppressive medications for autoimmune bullous disorders. Dermatol Clin 29(4):591\u2013598. https:\/\/doi.org\/10.1016\/j.det.2011.06.021","journal-title":"Dermatol Clin"},{"issue":"36","key":"2862_CR29","doi-asserted-by":"publisher","first-page":"5091","DOI":"10.1016\/j.vaccine.2021.07.050","volume":"39","author":"AJ Leidner","year":"2021","unstructured":"Leidner AJ, Tang Z, Guo A, Anderson TC, Tsai Y (2021) Insurance reimbursements for recombinant zoster vaccine in the private sector. Vaccine 39(36):5091\u20135094. https:\/\/doi.org\/10.1016\/j.vaccine.2021.07.050","journal-title":"Vaccine"},{"issue":"12","key":"2862_CR30","doi-asserted-by":"publisher","first-page":"2859","DOI":"10.1038\/jid.2008.178","volume":"128","author":"H Mouquet","year":"2008","unstructured":"Mouquet H, Musette P, Gougeon ML, Jacquot S, Lemercier B, Lim A, Gilbert D, Dutot I, Roujeau JC, D\u2019Incan M, Bedane C, Tron F, Joly P (2008) B-cell depletion immunotherapy in pemphigus: effects on cellular and humoral immune responses. J Invest Dermatol 128(12):2859\u20132869. https:\/\/doi.org\/10.1038\/jid.2008.178","journal-title":"J Invest Dermatol"},{"issue":"6","key":"2862_CR31","doi-asserted-by":"publisher","first-page":"1583","DOI":"10.1007\/s00403-023-02546-0","volume":"315","author":"MH Noe","year":"2023","unstructured":"Noe MH, Archila M, Barbieri JS, Goldman N, Lopez CG, Mostaghimi A, Scherer AM, Tan AJ, Perez-Chada LM, Asgari MM, Gelfand JM (2023) The patient perspective on vaccine uptake in adults with psoriasis and eczema. Arch Dermatol Res 315(6):1583\u20131592. https:\/\/doi.org\/10.1007\/s00403-023-02546-0","journal-title":"Arch Dermatol Res"},{"issue":"10","key":"2862_CR32","doi-asserted-by":"publisher","first-page":"1768","DOI":"10.1111\/jdv.14961","volume":"32","author":"Z Ren","year":"2018","unstructured":"Ren Z, Narla S, Hsu DY, Silverberg JI (2018) Association of serious infections with pemphigus and pemphigoid: analysis of the Nationwide Inpatient Sample. J Eur Acad Dermatol Venereol 32(10):1768\u20131776. https:\/\/doi.org\/10.1111\/jdv.14961","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"1","key":"2862_CR33","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1093\/rheumatology\/keac305","volume":"62","author":"P Sen","year":"2022","unstructured":"Sen P, Ravichandran N, Nune A, Lilleker JB, Agarwal V, Kardes S, Kim M, Day J, Milchert M, Gheita T, Salim B, Velikova T, Gracia-Ramos AE, Parodis I, Selva O\u2019Callaghan A, Nikiphorou E, Chatterjee T, Tan AL, Cavagna L, Saavedra MA, Shinjo SK, Ziade N, Knitza J, Kuwana M, Distler O, Chinoy H, Agarwal V, Aggarwal R, Gupta L, Group CS (2022) COVID-19 vaccination-related adverse events among autoimmune disease patients: results from the COVAD study. Rheumatology (Oxford) 62(1):65\u201376. https:\/\/doi.org\/10.1093\/rheumatology\/keac305","journal-title":"Rheumatology (Oxford)"},{"issue":"10","key":"2862_CR34","doi-asserted-by":"publisher","first-page":"1357","DOI":"10.1136\/annrheumdis-2021-220604","volume":"80","author":"R Spiera","year":"2021","unstructured":"Spiera R, Jinich S, Jannat-Khah D (2021) Rituximab, but not other antirheumatic therapies, is associated with impaired serological response to SARS- CoV-2 vaccination in patients with rheumatic diseases. Ann Rheum Dis 80(10):1357\u20131359. https:\/\/doi.org\/10.1136\/annrheumdis-2021-220604","journal-title":"Ann Rheum Dis"},{"issue":"6","key":"2862_CR35","doi-asserted-by":"publisher","first-page":"349","DOI":"10.1093\/intqhc\/mzm042","volume":"19","author":"A Tong","year":"2007","unstructured":"Tong A, Sainsbury P, Craig J (2007) Consolidated criteria for reporting qualitative research (COREQ): a 32-item checklist for interviews and focus groups. Int J Qual Health Care 19(6):349\u2013357. https:\/\/doi.org\/10.1093\/intqhc\/mzm042","journal-title":"Int J Qual Health Care"},{"issue":"1","key":"2862_CR36","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1002\/art.25033","volume":"62","author":"S van Assen","year":"2010","unstructured":"van Assen S, Holvast A, Benne CA, Posthumus MD, van Leeuwen MA, Voskuyl AE, Blom M, Risselada AP, de Haan A, Westra J, Kallenberg CG, Bijl M (2010) Humoral responses after influenza vaccination are severely reduced in patients with rheumatoid arthritis treated with rituximab. Arthritis Rheum 62(1):75\u201381. https:\/\/doi.org\/10.1002\/art.25033","journal-title":"Arthritis Rheum"},{"issue":"6","key":"2862_CR37","doi-asserted-by":"publisher","first-page":"2257","DOI":"10.1182\/blood.V100.6.2257","volume":"100","author":"LE van der Kolk","year":"2002","unstructured":"van der Kolk LE, Baars JW, Prins MH, van Oers MH (2002) Rituximab treatment results in impaired secondary humoral immune responsiveness. Blood 100(6):2257\u20132259. https:\/\/doi.org\/10.1182\/blood.V100.6.2257","journal-title":"Blood"},{"issue":"24","key":"2862_CR38","doi-asserted-by":"publisher","first-page":"2295","DOI":"10.1056\/NEJMoa2028564","volume":"384","author":"VP Werth","year":"2021","unstructured":"Werth VP, Joly P, Mimouni D, Maverakis E, Caux F, Lehane P, Gearhart L, Kapre A, Pordeli P, Chen DM, Group PS (2021) Rituximab versus Mycophenolate Mofetil in patients with Pemphigus Vulgaris. N Engl J Med 384(24):2295\u20132305. https:\/\/doi.org\/10.1056\/NEJMoa2028564","journal-title":"N Engl J Med"},{"issue":"33","key":"2862_CR39","doi-asserted-by":"publisher","first-page":"5131","DOI":"10.1016\/j.vaccine.2020.04.076","volume":"38","author":"X Xiao","year":"2020","unstructured":"Xiao X, Wong RM (2020) Vaccine hesitancy and perceived behavioral control: a meta-analysis. Vaccine 38(33):5131\u20135138. https:\/\/doi.org\/10.1016\/j.vaccine.2020.04.076","journal-title":"Vaccine"},{"issue":"4","key":"2862_CR40","doi-asserted-by":"publisher","first-page":"746","DOI":"10.1093\/pubmed\/fdv194","volume":"38","author":"MP Yeung","year":"2016","unstructured":"Yeung MP, Lam FL, Coker R (2016) Factors associated with the uptake of seasonal influenza vaccination in adults: a systematic review. J Public Health (Oxf) 38(4):746\u2013753. https:\/\/doi.org\/10.1093\/pubmed\/fdv194","journal-title":"J Public Health (Oxf)"}],"container-title":["Archives of Dermatological Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00403-024-02862-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00403-024-02862-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00403-024-02862-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,6,4]],"date-time":"2024-06-04T09:46:41Z","timestamp":1717494401000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00403-024-02862-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,4,18]]},"references-count":40,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2024,7]]}},"alternative-id":["2862"],"URL":"https:\/\/doi.org\/10.1007\/s00403-024-02862-z","relation":{},"ISSN":["1432-069X"],"issn-type":[{"value":"1432-069X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,4,18]]},"assertion":[{"value":"22 December 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 December 2023","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 April 2024","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 April 2024","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Maryam Asgari receives royalty payments from UptoDate.John Barbieri is an Associate Editor for JAMA Dermatology.Joel Gelfand served as a consultant for Bristol-Myers Squibb, Boehringer Ingelheim, GlaxoSmithKline, Janssen Biologics, Novartis Corp, Regeneron, UCB (Data Safety and Monitoring Board), and Sanofi and Pfizer Inc, receiving honoraria; in addition, he receives research grants (to the Trustees of the University of Pennsylvania) from Abbvie, Janssen, Novartis Corp, Sanofi, Celgene, OrthoDermatologics, and Pfizer Inc, and he has received payment for CME work related to psoriasis that was supported indirectly by Eli Lilly and Company and Ortho Dermatologics. In addition, Joel Gelfand is a co-patent holder of resiquimod for treatment of cutaneous T-cell lymphoma and is the deputy editor deputy editor for the Journal of Investigative Dermatology, receiving honoraria from the Society for Investigative Dermatology and is the Chief Medical Editor for Healio Psoriatic Disease for which he received honoraria.Arash Mostaghimi has received consulting fees from Pfizer, hims and hers, Digital Diagnostics, Concert, Lilly, Abbvie, Bioniz, Acom, Equillium, Boerhringer Ingelheim; equity from hims, Fig.\u00a01, ACOM; licensing\/royalties from Pfizer, Concert; and research funding from Incyte, Lilly, Aclaris, Concert.Megan Noe has received research grants from Boehringer Ingelheim and Bristol Myers Squibb. She is a consultant for Boehringer Ingelheim and Argenx and received honoraria. She is a senior editor for the Journal of Psoriasis and Psoriatic Arthritis.Aaron Scherer, Marjorie Archila, Lourdes M. Perez-Chada, and Alice J. Tan have nothing to disclose.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"This study was deemed exempt (Category 2) by the Mass General Brigham IRB (Protocol #001856). Verbal consent was obtained from participants prior to participation.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"All authors listed qualify for authorship according to the ICJME guidelines and agree to the manuscript\u2019s submission.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}}],"article-number":"125"}}